Tags

Type your tag names separated by a space and hit enter

The role of bisphosphonates in breast cancer.
Breast. 2004 Dec; 13 Suppl 1:S19-28.B

Abstract

Patients with bone metastases from breast cancer are at high risk for debilitating skeletal complications. Bisphosphonates are effective inhibitors of tumour-induced bone resorption and significantly reduce the risk of skeletal complications in these patients. Several bisphosphonates have been investigated for the treatment of bone metastases in patients with breast cancer, including clodronate, pamidronate, ibandronate, and zoledronic acid. Among these agents, intravenous pamidronate and zoledronic acid have demonstrated the greatest clinical benefit based on conservative endpoints. Zoledronic acid is the only agent to be compared with another active bisphosphonate and has been shown to significantly reduce the risk of skeletal complications compared with pamidronate. On the basis of these results, zoledronic acid has rapidly become the new international standard of care for patients with bone metastases from breast cancer.

Authors+Show Affiliations

Cancer Research Centre, YCR Academic Unit of Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK. r.e.coleman@sheffield.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15585379

Citation

Coleman, Robert E.. "The Role of Bisphosphonates in Breast Cancer." Breast (Edinburgh, Scotland), vol. 13 Suppl 1, 2004, pp. S19-28.
Coleman RE. The role of bisphosphonates in breast cancer. Breast. 2004;13 Suppl 1:S19-28.
Coleman, R. E. (2004). The role of bisphosphonates in breast cancer. Breast (Edinburgh, Scotland), 13 Suppl 1, S19-28.
Coleman RE. The Role of Bisphosphonates in Breast Cancer. Breast. 2004;13 Suppl 1:S19-28. PubMed PMID: 15585379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of bisphosphonates in breast cancer. A1 - Coleman,Robert E, PY - 2004/12/9/pubmed PY - 2005/3/16/medline PY - 2004/12/9/entrez SP - S19 EP - 28 JF - Breast (Edinburgh, Scotland) JO - Breast VL - 13 Suppl 1 N2 - Patients with bone metastases from breast cancer are at high risk for debilitating skeletal complications. Bisphosphonates are effective inhibitors of tumour-induced bone resorption and significantly reduce the risk of skeletal complications in these patients. Several bisphosphonates have been investigated for the treatment of bone metastases in patients with breast cancer, including clodronate, pamidronate, ibandronate, and zoledronic acid. Among these agents, intravenous pamidronate and zoledronic acid have demonstrated the greatest clinical benefit based on conservative endpoints. Zoledronic acid is the only agent to be compared with another active bisphosphonate and has been shown to significantly reduce the risk of skeletal complications compared with pamidronate. On the basis of these results, zoledronic acid has rapidly become the new international standard of care for patients with bone metastases from breast cancer. SN - 0960-9776 UR - https://www.unboundmedicine.com/medline/citation/15585379/The_role_of_bisphosphonates_in_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0960-9776(04)00145-6 DB - PRIME DP - Unbound Medicine ER -